The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with ...

Biocon Ltd’s share price fell 4.86 per cent on January 27, 2025, hitting a day’s low of Rs 369.40 on the NSE, while the NIFTY ...

Biocon Ltd on Monday said its board has approved raising Rs 570 crore through issuance of commercial papers on private ...

Biocon in its Environmental, Social and Governance (ESG) scores as assessed by S&P Global’s Corporate Sustainability Assessment (CSA) for 2024 has achieved an improvement to 69 in 2024, up 6 points ...

Bengaluru: Biocon Limited, a global biopharmaceuticals company, has announced its Environmental, Social and Governance (ESG) ...

SMC Global Securities said that Eicher Motors has been trading within a well-defined channel, and a breakout has occurred on ...

Biocon announced its Environmental, Social and Governance (ESG) scores as assessed by S&P Global's Corporate Sustainability Assessment (CSA) for 2024. Biocon achieved a notable improvement with an S&P ...

According to his brother Revanasiddappa, who works as a driver, Nagesh had no prior health issues before participating in the trial.

Syngene International declined 6.17% to Rs 795 after the company projected single-digit revenue growth and flat profit after tax (PAT) for the full year, with unchanged EBITDA guidance.

Critical pain points need to be overcome for the animal healthcare industry to achieve its full potential.

Syngene International revised its revenue expectations due to further delays in the US biotech funding environment during the third quarter.

In his complaint, Revanasiddappa, who works as a driver, said that his brother did not have any health issues before becoming ...